Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease.

Cheng WC, Weng CY, Yun WY, Chang SY, Lin YC, Tsai FJ, Huang FY, Chen YR.

Bioorg Med Chem. 2013 Sep 1;21(17):5021-8. doi: 10.1016/j.bmc.2013.06.054.

PMID:
23880081
2.

Human Acid β-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease.

Parmeggiani C, Catarzi S, Matassini C, D'Adamio G, Morrone A, Goti A, Paoli P, Cardona F.

Chembiochem. 2015 Sep 21;16(14):2054-64. doi: 10.1002/cbic.201500292.

PMID:
26376302
3.

A systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of Gaucher disease.

Joosten A, Decroocq C, de Sousa J, Schneider JP, Etamé E, Bodlenner A, Butters TD, Compain P.

Chembiochem. 2014 Jan 24;15(2):309-19. doi: 10.1002/cbic.201300442.

PMID:
24375964
4.
5.

Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.

Luan Z, Higaki K, Aguilar-Moncayo M, Ninomiya H, Ohno K, García-Moreno MI, Ortiz Mellet C, García Fernández JM, Suzuki Y.

Chembiochem. 2009 Nov 23;10(17):2780-92. doi: 10.1002/cbic.200900442.

PMID:
19830760
6.

Amphiphilic 1-deoxynojirimycin derivatives through click strategies for chemical chaperoning in N370S Gaucher cells.

Diot JD, Garcia Moreno I, Twigg G, Ortiz Mellet C, Haupt K, Butters TD, Kovensky J, Gouin SG.

J Org Chem. 2011 Oct 7;76(19):7757-68. doi: 10.1021/jo201125x.

PMID:
21830816
7.

Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease.

Kato A, Nakagome I, Sato K, Yamamoto A, Adachi I, Nash RJ, Fleet GW, Natori Y, Watanabe Y, Imahori T, Yoshimura Y, Takahata H, Hirono S.

Org Biomol Chem. 2016 Jan 21;14(3):1039-48. doi: 10.1039/c5ob02223a.

PMID:
26633162
8.

Glucocerebrosidase inhibitors for the treatment of Gaucher disease.

Trapero A, Llebaria A.

Future Med Chem. 2013 Apr;5(5):573-90. doi: 10.4155/fmc.13.14. Review.

PMID:
23573974
9.

Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.

Yu L, Ikeda K, Kato A, Adachi I, Godin G, Compain P, Martin O, Asano N.

Bioorg Med Chem. 2006 Dec 1;14(23):7736-44.

PMID:
16919960
10.

Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.

Trapero A, Alfonso I, Butters TD, Llebaria A.

J Am Chem Soc. 2011 Apr 13;133(14):5474-84. doi: 10.1021/ja111480z.

PMID:
21413704
11.

Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.

Mena-Barragán T, García-Moreno MI, Nanba E, Higaki K, Concia AL, Clapés P, García Fernández JM, Ortiz Mellet C.

Eur J Med Chem. 2016 Oct 4;121:880-91. doi: 10.1016/j.ejmech.2015.08.038.

PMID:
26361824
12.

Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease.

Wang GN, Twigg G, Butters TD, Zhang S, Zhang L, Zhang LH, Ye XS.

Org Biomol Chem. 2012 Apr 21;10(15):2923-7. doi: 10.1039/c2ob06987c.

PMID:
22286559
13.

Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease.

Schönemann W, Gallienne E, Ikeda-Obatake K, Asano N, Nakagawa S, Kato A, Adachi I, Górecki M, Frelek J, Martin OR.

ChemMedChem. 2013 Nov;8(11):1805-17. doi: 10.1002/cmdc.201300327.

PMID:
24115322
14.

Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.

Wang GN, Reinkensmeier G, Zhang SW, Zhou J, Zhang LR, Zhang LH, Butters TD, Ye XS.

J Med Chem. 2009 May 28;52(10):3146-9. doi: 10.1021/jm801506m.

PMID:
19397268
15.

Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.

Sánchez-Ollé G, Duque J, Egido-Gabás M, Casas J, Lluch M, Chabás A, Grinberg D, Vilageliu L.

Blood Cells Mol Dis. 2009 Mar-Apr;42(2):159-66. doi: 10.1016/j.bcmd.2008.11.002.

PMID:
19167250
16.

Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease.

Trapero A, González-Bulnes P, Butters TD, Llebaria A.

J Med Chem. 2012 May 10;55(9):4479-88. doi: 10.1021/jm300342q.

PMID:
22512696
17.

Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.

Lieberman RL, Wustman BA, Huertas P, Powe AC Jr, Pine CW, Khanna R, Schlossmacher MG, Ringe D, Petsko GA.

Nat Chem Biol. 2007 Feb;3(2):101-7.

PMID:
17187079
18.

Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher disease.

Alfonso P, Andreu V, Pino-Angeles A, Moya-García AA, García-Moreno MI, Rodríguez-Rey JC, Sánchez-Jiménez F, Pocoví M, Ortiz Mellet C, García Fernández JM, Giraldo P.

Chembiochem. 2013 May 27;14(8):943-9. doi: 10.1002/cbic.201200708.

PMID:
23606264
19.

N- and C-alkylation of seven-membered iminosugars generates potent glucocerebrosidase inhibitors and F508del-CFTR correctors.

Désiré J, Mondon M, Fontelle N, Nakagawa S, Hirokami Y, Adachi I, Iwaki R, Fleet GW, Alonzi DS, Twigg G, Butters TD, Bertrand J, Cendret V, Becq F, Norez C, Marrot J, Kato A, Blériot Y.

Org Biomol Chem. 2014 Nov 28;12(44):8977-96. doi: 10.1039/c4ob00325j.

PMID:
25277226
20.

Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.

Tropak MB, Kornhaber GJ, Rigat BA, Maegawa GH, Buttner JD, Blanchard JE, Murphy C, Tuske SJ, Coales SJ, Hamuro Y, Brown ED, Mahuran DJ.

Chembiochem. 2008 Nov 3;9(16):2650-62. doi: 10.1002/cbic.200800304.

Supplemental Content

Support Center